Overview

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

Status:
Recruiting
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Phase:
Phase 1
Details
Lead Sponsor:
Allyx Therapeutics
Collaborators:
National Institute on Aging (NIA)
Yale University